Denosumab Monoclonal Antibody Cas 615258-40-7

Denosumab, which was approved in the United States in 2010, is a fully human sequence IgG2 monoclonal antibody that inhibits bone resorption by blocking the activity of receptor activator of nuclear factor-κB ligand (RANKL). RANKL is a TNF family protein that is expressed in both secreted and cell surface forms by a variety of bone marrow cell types andmediates bone resorption through its receptor (RANK),which is found on osteoclasts and osteoclast precursors . Denosumab was discovered using XenomouseTM transgenic mice comprising human immunoglobulin genes. The antibody is approved for treatment of postmenopausal women with osteoporosis at high risk for fracture, and for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Denosumab competes directly with bisphosphonates such as alendronic acid in postmenopausal osteoporosis and with zoledronic acid in both of these indications. It has been shown to have comparable efficacy and safety to bisphosphonates with some tolerability and patient acceptability advantages.

Related Products:

Alirocumab; Eculizumab; Evolocumab; Omalizumab; Ustekinumab; Vedolizumab; Trastuzumab; Omalizumab; Nivolumab; Denosumab; Cetuximab; Bevacizumab; Aflibercept